Eric A. Secemsky, Freelance Journalist Profile

Articles

On versus Off Label Device Techniques for Percutaneous Deep Venous Arterialisation

1 month ago | ejves.com | Eric A. Secemsky

1Department of Surgery, University of Texas Medical Branch, Galveston, TX, USA 2Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA, USA 3Department of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA Publication History: Received March 10, 2025; Revised March 13, 2025; Accepted March 18, 2025; Published online March 23, 2025 DOI: 10.1016/j.ejvs.2025.03.024Also available on ScienceDirect Copyright: © 2025 Published by Elsevier...
Future Direction for RDN: From Hypertension to AFib and Beyond

1 month ago | hmpgloballearningnetwork.com | Eric A. Secemsky

In this video from CRT 2025, JIC speaks with Dr Eric Secemsky of the Beth Israel Deaconness Medical Center about the future of renal denervation in atrial fibrillation treatment. Transcript:Hi, I'm Eric Secemsky. I'm an interventional cardiologist at the Beth Israel Deaconess Medical Center in Boston, Massachusetts. Can you please briefly explain the physiological link between the renal system and AFib?
Bioabsorbable Scaffolds: A Revolution Below the Knee?

2 months ago | hmpgloballearningnetwork.com | Eric A. Secemsky

LINC 2025 Recent and forthcoming trials of bioabsorbable scaffolds were outlined this morning by Eric A. Secemsky, Director of the Vascular Intervention Department at the Beth Israel Deaconess Medical Center in Boston, Massachusetts. An interventional cardiologist, Dr Secemsky was involved in the LIFE-BTK clinical trial,1 which brought the first bioabsorbable scaffold, the ESPRIT DRS (Abbott Vascular) to the U.S. market.
SAFE-IVC Study Finds Declining Use of IVC Filters But Need for Improved Rates of Timely Retrieval

Jan 17, 2025 | evtoday.com | Eric A. Secemsky

In a large, real-world analysis of United States Medicare fee-for-service patients, Ferro et al found that inferior vena cava filter (IVC) use declined over the study period, but the cumulative rate of retrieval was low, suggesting a need for strategies to achieve timely retrieval. The results were published in JAMA.1 The SAFE-IVC study was designed in collaboration with the FDA in an effort to better understand contemporary IVC filter use and outcomes.
Short and Mid Term Outcomes of Percutaneous Deep Venous Arterialisation for No-option Chronic Limb Threatening Ischaemia: A Systematic Review and Meta-Analysis

Aug 8, 2024 | ejves.com | Martin Orrukem |Eric A. Secemsky |Albert Einstein College

This paper is only available as a PDF. To read, Please Download here. Percutaneous deep venous arterialisation (pDVA) is a state of the art technique for treating patients with chronic limb threatening ischaemia (CLTI) with no conventional option for revascularisation. There are limited large scale data examining the clinical effectiveness of pDVA for patients with end stage CLTI. MEDLINE, Embase, Google Scholar, and Cochrane databases.
Renal Denervation: How We Do It

Apr 17, 2024 | hmpgloballearningnetwork.com | Eric A. Secemsky

Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI, FSVMDirector, Vascular Intervention, Beth Israel Deaconess Medical Center; Section Head, Interventional Cardiology and Vascular Research, Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center; Associate Professor of Medicine, Harvard Medical School, Boston, MassachusettsDisclosures: Dr. Secemsky reports he is a consultant to Medtronic and his institution receives funding from Medtronic.
Planning for Renal Denervation in Your Practice

Mar 18, 2024 | hmpgloballearningnetwork.com | Eric A. Secemsky

The Freesolve BTK RMS Is Designed for Patients Suffering From Chronic Limb-Threatening Ischemia (CLTI) BÜLACH, Switzerland – March 18, 2024. BIOTRONIK has been granted Breakthrough Device Designation (BDD) from the US Food and Drug... The Freesolve BTK RMS Is Designed for Patients Suffering From Chronic Limb-Threatening Ischemia (CLTI) BÜLACH, Switzerland – March 18, 2024. BIOTRONIK has been granted Breakthrough Device Designation (BDD) from the US Food and Drug...
Expert panel: IVUS can benefit patients needing peripheral revascularization

Jan 9, 2024 | healio.com | Erik Swain |Richard Smith |Eric A. Secemsky

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways:IVUS may improve care of patients undergoing peripheral revascularization. More data are needed to document benefits and develop better appropriate use criteria.
Creative, Collaborative Approaches

Jan 20, 2023 | evtoday.com | Anahita Dua |Eric A. Secemsky

Although the concept of collaborative multidisciplinary approaches to patient care is neither new nor specific to vascular disease, the trend toward building dedicated teams across our specialties continues to gain traction in the field, with good reason. The benefits of team-based approaches are countless, most notably the diversity of expertise and skill sets they provide.